Karoline Anisdahl, Oslo University Hospital, Norway, and her colleagues aimed to assess whether there was a change over time in the proportion of patients receiving biologics between 2011 and 2016 and if the preferred first-line biologic changed after the introduction of biosimilar infliximab. Click and hear the highlights from the study.  

In this MEDtalk Brian Bressler present data from amulti-country, retrospective chart review study assessed the effectiveness and safety of vedolizumab compared with anti-tumour necrosis factors  agents in a real-world cohort of biologic-naïve Crohn’s disease patients. Click and hear the result.  

UC and CD increased the risk of Type 2 Diabetes

This Danish population-based cohort study shows an increased risk of T2D both in patients with UC and CD. Whether the significantly higher risk of T2D observed in recent years reflects an impact of current treatment options in IBD remains to be investigated.  

This study aimed to compare the real-world clinical effectiveness and safety of vedolizumab, a gut-selective anti-α4β7-integrin, and anti-TNF agents in biologic (bio)-naïve ulcerative colitis (UC) patients. Click and hear the results, presented by Andres Yarur.  

Patients with inflammatory bowel disease are at risk of developing metabolic bone disease. At the same time no general agreement regarding osteoporosis screening in IBD patients exists. This study shows with 10 years of follow up, that increased attention to IBD patient at risk of metabolic bone disease must be prioritized and guidelines on this matter are warranted. Click and hear the results of the study.  

Crohn's disease (CD) and ulcerative colitis (UC) carries a high burden on healthcare resources. To date, no study has assessed the combined direct and indirect cost of inflammatory bowel disease (IBD) in a population-based setting. Click and hear the interesting result from a population-based inception cohort with 10 years of follow-up, here presenting by Bobby Zhao Sheng Lo.